What was the market valuation of macrolide antibiotics in the US in 2024?

The market valuation of macrolide antibiotics in the US was $13.9 Billion in 2024. Read More

What is the projected market valuation for macrolide antibiotics by 2035?

The projected market valuation for macrolide antibiotics is $56.5 Billion by 2035. Read More

What is the expected CAGR for the US macrolide antibiotics market during the forecast period 2025 - 2035?

The expected CAGR for the US macrolide antibiotics market during the forecast period 2025 - 2035 is 13.6%. Read More

Which macrolide antibiotic had the highest market valuation in 2024?

Azithromycin had the highest market valuation at $5.0 Billion in 2024. Read More

What are the projected market values for oral and parenteral routes of administration by 2035?

The projected market values for oral and parenteral routes of administration are $28.65 Billion and $27.85 Billion, respectively, by 2035. Read More

Which end user segment is expected to dominate the macrolide antibiotics market by 2035?

Hospitals are expected to dominate the macrolide antibiotics market with a projected valuation of $20.0 Billion by 2035. Read More

What is the market value range for clarithromycin from 2024 to 2035?

The market value range for clarithromycin is projected to increase from $3.0 Billion in 2024 to $12.0 Billion by 2035. Read More

Which key players are leading the US macrolide antibiotics market?

Key players leading the US macrolide antibiotics market include Pfizer Inc, Merck & Co Inc, and AbbVie Inc. Read More

What is the projected market value for infections due to Mycoplasma pneumoniae by 2035?

The projected market value for infections due to Mycoplasma pneumoniae is $6.2 Billion by 2035. Read More

How does the market value for symptomatic cat-scratch disease change from 2024 to 2035?

The market value for symptomatic cat-scratch disease is projected to increase from $0.8 Billion in 2024 to $3.5 Billion by 2035. Read More

US Macrolide Antibiotics Market

ID: MRFR/Pharma/16780-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Macrolide Antibiotics Market Research Report: Size, Share, Trend Analysis By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin), By Route of Administration (Oral, Parenteral), By Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, Others) and By End Users (Hospitals, Dermatology Clinics, Pharmaceutical Companies, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Drug (USD Billion)
  1. 4.1.1 Azithromycin
  2. 4.1.2 Clarithromycin
  3. 4.1.3 Erythromycin
  4. 4.1.4 Fidaxomicin
  5. 4.1.5 Telithromycin
2. 4.2 Food, Beverages & Nutrition, BY Route of Administration (USD Billion)
  1. 4.2.1 Oral
  2. 4.2.2 Parenteral
3. 4.3 Food, Beverages & Nutrition, BY Indication (USD Billion)
  1. 4.3.1 Infection Due to Mycoplasma Pneumoniae
  2. 4.3.2 Legionella Sp, or Bordetella Pertussis
  3. 4.3.3 Symptomatic Cat-Scratch Disease
  4. 4.3.4 Bacillary Angiomatosis
  5. 4.3.5 Peliosis Hepatis in Patients with AIDS
  6. 4.3.6 Cerebral Toxoplasmosis
  7. 4.3.7 Uncomplicated Skin Infections
  8. 4.3.8 Others
4. 4.4 Food, Beverages & Nutrition, BY End User (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Dermatology Clinics
  3. 4.4.3 Pharmaceutical Companies
  4. 4.4.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 AstraZeneca PLC (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb Company (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AbbVie Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi S.A. (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GSK PLC (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 TO 2035 (USD Billion)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Billion)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG, 2025-2035 (USD Billion)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Drug (USD Billion, 2025-2035)

Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin

Food, Beverages & Nutrition By Route of Administration (USD Billion, 2025-2035)

Oral
Parenteral

Food, Beverages & Nutrition By Indication (USD Billion, 2025-2035)

Infection Due to Mycoplasma Pneumoniae
Legionella Sp, or Bordetella Pertussis
Symptomatic Cat-Scratch Disease
Bacillary Angiomatosis
Peliosis Hepatis in Patients with AIDS
Cerebral Toxoplasmosis
Uncomplicated Skin Infections
Others

Food, Beverages & Nutrition By End User (USD Billion, 2025-2035)

Hospitals
Dermatology Clinics
US Macrolide Antibiotics Market Companies
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”